• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/13/25 5:00:08 PM ET
    $NVCT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVCT alert in real time by email
    false 0001875558 0001875558 2025-06-12 2025-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 12, 2025

     

    Nuvectis Pharma, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware
    (State or Other Jurisdiction
    of Incorporation)
      001-41264
    (Commission File Number)
      86-2405608
    (IRS Employer Identification No.)

     

    1 Bridge Plaza Suite 275

    Fort Lee, NJ 07024

    (Address of Principal Executive Offices)

     

    (201) 614-3150

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act.
       
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
       
    ¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
       
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

     

    Securities registered pursuant to Section 12(b) of the Exchange Act:

     

    Title of Class Trading Symbol(s) Exchange Name
    Common Stock NVCT Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    On Thursday, June 12, 2025, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Stockholders representing 14,605,167, or 61.86%, of the 23,606,443 shares of common stock outstanding on the record date of April 14, 2025, were present in person or by proxy, constituting a quorum under applicable law. Proxies were solicited by the Company pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. Each of the proposals below are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2025 Annual Meeting, filed with the SEC on April 28, 2025. At the 2025 Annual Meeting, all of the proposals were approved.

     

    The results are as follows:

     

    Proposal 1

     

    The votes with respect to the election of the Class III director to hold office until the 2028 annual meeting was as follows:

     

    Director  Votes For   Votes
    Against
       Abstentions /
    Votes Withheld
       Broker
    Non-Votes
     
    James Oliviero   9,882,555    240,327    782    4,481,503 

     

    Proposal 2

     

    The vote with respect to the ratification of Kesselman & Kesselman as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was as follows:

     

    Votes For   Votes Against   Abstentions / Votes Withheld   Broker Non-Votes 
     14,561,983    40,324    2,860    - 

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Nuvectis Pharma, Inc.
      (Registrant)
         
    Date: June 13, 2025    
      By: /s/ Ron Bentsur
        Ron Bentsur
        Chairman, Chief Executive Officer and President

     

     

     

    Get the next $NVCT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NVCT

    DatePrice TargetRatingAnalyst
    4/2/2025$17.00Buy
    Maxim Group
    3/17/2025$19.00Buy
    Laidlaw
    7/13/2022$21.00Buy
    Ladenburg Thalmann
    3/2/2022$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $NVCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/24/25 5:14:35 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/20/25 9:50:29 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $171,664 worth of shares (21,167 units at $8.11) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      5/13/25 6:36:36 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Nuvectis Pharma with a new price target

      Maxim Group initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $17.00

      4/2/25 8:05:05 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw initiated coverage on Nuvectis Pharma with a new price target

      Laidlaw initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $19.00

      3/17/25 7:40:44 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

      Ladenburg Thalmann initiated coverage of Nuvectis Pharma with a rating of Buy and set a new price target of $21.00

      7/13/22 8:35:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Mosseri Marlio Charles bought $44,768 worth of shares (5,603 units at $7.99) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/24/25 5:14:35 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Mosseri Marlio Charles bought $269,532 worth of shares (33,442 units at $8.06) (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/20/25 9:50:29 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kaplan Matthew L. was granted 30,000 shares, increasing direct ownership by 36% to 113,760 units (SEC Form 4)

      4 - Nuvectis Pharma, Inc. (0001875558) (Issuer)

      6/12/25 4:31:16 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies

      Drug-drug interaction ("DDI") clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs.The market leading epidermal growth factor receptor ("EGFR") and anaplastic lymphoma kinase ("ALK") inhibitors for the treatment of non-small cell lung cancer ("NSCLC") are substrates of the Cytochrome P450 ("CYP") enzyme CYP3A, and therefore their combination with drugs that are strong inducers of CYP3A is to be avoided, or is contraindicated.As per the International Council for Harmonization ("ICH") M12, topline results from the NXP900 DDI clinical study classify NXP900 as a weak inhibitor

      7/8/25 8:00:00 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

      Fort Lee, NJ, May 16, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. Event3rd Annual H.C. Wainwright BioConnect Investor ConferenceDateMay 20th, 2025Time10:30 – 11:00 a.m. ETLinkNuvectis Pharma Presentation Webcast Link About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a biopharmaceutical company focused on

      5/16/25 4:35:00 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

      NXP900 clinical data presentation from the Phase 1a dose escalation study at the 2025 American Association for Cancer Research (AACR) conference demonstrated robust pharmacodynamic response and acceptable safety at clinically relevant doses; preclinical data presentations further strengthen the clinical development strategyCompleted $15.5M financing, extending projected cash runway into 1Q2027 FORT LEE, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod

      5/6/25 8:00:11 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    SEC Filings

    See more
    • Nuvectis Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

      6/13/25 5:00:08 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:20:51 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Nuvectis Pharma Inc.

      424B5 - Nuvectis Pharma, Inc. (0001875558) (Filer)

      5/9/25 5:12:42 PM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      11/5/24 10:55:09 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

      SC 13G/A - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/28/24 8:37:52 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Nuvectis Pharma Inc.

      SC 13G - Nuvectis Pharma, Inc. (0001875558) (Subject)

      2/6/24 8:47:33 AM ET
      $NVCT
      Biotechnology: Pharmaceutical Preparations
      Health Care